Integrated Filing — IndAS



General information about company
Scrip Code 532815
NSE Symbol SMSPHARMA
MSEI Symbol NOTLISTED
ISIN INE812G01025
Name of company SMS PHARMACEUTICALS LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 30-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 23-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Bulk Drugs
Start date and time of board meeting 30-May-2025   10:30:00
End date and time of board meeting 30-May-2025   16:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2024-11-08
Indicate Company website link for updated RPT policy of the Company https://smspharma.com/corporate-governance/governance-documents-policies/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable as there is no default



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 2481956000 7827481000
Other income 14241000 62244000
Total income 2496197000 7889725000
2 Expenses
(a) Cost of materials consumed 1170101000 5008977000
(b) Purchases of stock-in-trade 0 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 303712000 -648139000
(d) Employee benefit expense 266300000 800842000
(e) Finance costs 50650000 185409000
(f) Depreciation, depletion and amortisation expense 86399000 343373000
(f) Other Expenses
1 Manufacturing Expenses 254080000 863504000
2 Other Expenses 74311000 402554000
Total other expenses 328391000 1266058000
Total expenses 2205553000 6956520000
3 Total profit before exceptional items and tax 290644000 933205000
4 Exceptional items 0 0
5 Total profit before tax 290644000 933205000
6 Tax expense
7 Current tax 46500000 196406000
8 Deferred tax 37920000 52987000
9 Total tax expenses 84420000 249393000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 206224000 683812000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 206224000 683812000
17 Other comprehensive income net of taxes -5490000 -5035000
18 Total Comprehensive Income for the period 200734000 678777000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 88652000 88652000
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 6642045000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 2.43 8.07
Diluted earnings (loss) per share from continuing operations 2.43 8.07
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 2.43 8.07
Diluted earnings (loss) per share from continuing and discontinued operations 2.43 8.07
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 5308479000
Capital work-in-progress 346714000
Investment property 0
Goodwill 0
Other intangible assets 21296000
Intangible assets under development 0
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 451060000
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 98930000
Total non-current financial assets 549990000
Deferred tax assets (net) 0
Other non-current assets 89923000
Total non-current assets 6316402000
2 Current assets
Inventories 2847292000
Current financial asset
Current investments 0
Trade receivables, current 2032336000
Cash and cash equivalents 413927000
Bank balance other than cash and cash equivalents 1870000
Loans, current 0
Other current financial assets 98926000
Total current financial assets 2547059000
Current tax assets (net) 3871000
Other current assets 146394000
Total current assets 5544616000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 11861018000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 88652000
Other equity 6642045000
Total equity attributable to owners of parent 6730697000
Non controlling interest
Total equity 6730697000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 1393642000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 0
Total non-current financial liabilities 1393642000
Provisions, non-current 12065000
Deferred tax liabilities (net) 480976000
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 1886683000
Current liabilities
Current financial liabilities
Borrowings, current 1713915000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 964000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1138157000
Total Trade payable 1139121000
Other current financial liabilities 333672000
Total current financial liabilities 3186708000
Other current liabilities 45850000
Provisions, current 11080000
Current tax liabilities (Net) 0
Deferred government grants, Current 0
Total current liabilities 3243638000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 5130321000
Total equity and liabilites 11861018000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 5490000 5035000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income -5490000 -5035000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 933205000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 174314000
Adjustments for decrease (increase) in inventories -510313000
Adjustments for decrease (increase) in trade receivables, current 329994000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets 96490000
Adjustments for decrease (increase) in other non-current assets 48789000
Adjustments for other financial assets, non-current -17774000
Adjustments for other financial assets, current -65731000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current -374108000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities -34000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 343373000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 0
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 61857000
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for interest income 2078000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow -205000
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items -2326000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 82248000
Net cash flows from (used in) operations 1015453000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 198334000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 817119000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 560000
Purchase of property, plant and equipment 1233798000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 1669000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -2811000
Net cash flows from (used in) investing activities -1234380000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 380903000
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 637238000
Repayments of borrowings 440966000
Payments of lease liabilities 7022000
Dividends paid 33861000
Interest paid 173529000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 108030000
Net cash flows from (used in) financing activities 470793000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 53532000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 53532000
Cash and cash equivalents cash flow statement at beginning of period 360395000
Cash and cash equivalents cash flow statement at end of period 413927000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M/s.Suryanarayana & Suresh, Chartered Accountants Yes 31-Jul-2026


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)
Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 19-Mar-2024
Amount Raised 1143000000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CARE Ratings Limited
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation NIL
Comments of the Audit Committee after review NIL
Comments of the auditors, if any NIL
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Capital Expenditure: Expansion of production capacities in phased manner and installation of additional utility equipments as well as recovery systems. Proposed to start backward integration of Key Starting Materials (KSM) for existing as well as new products under pipeline at R&D by setting up new production blocks. NA 628700000 0 171400000 0 The Total issue size is Rs. 11430 (in lakhs). 1. The company has received Rs. 2857 (in lakhs) on 19.03.2024 as 25% upfront payment and allotted 90,00,000 warrants. 2. During this quarter on 27.03.2025, 40,00,000 warrants has been converted into equity shares on receipt of balance 75% amount i.e. Rs. 3810 (in lakhs).
2 Working Capital: Expanding the production capacities, backward integration of KSM, which led to an increased requirement of Working Capital, operational expenditure and other related expenses. NA 400000000 0 114300000 0 Upto the quarter ended December 31, 2024, the Company had temporarily utilized the funds for working capital purposes. However, during the current quarter, the funds have been utilized in line with the objects of the issue.
3 General Corporate Purposes: which includes, inter alia, meeting ongoing general corporate exigencies and contingencies, expenses of the Company as applicable in such a manner and proportion as may be decided by the Board from time to time, and/or any other general purposes as may be permissible under applicable laws. NA 114300000 0 0 0


Signatory Details
Name of signatory Lakshmi Narayana Tammineedi
Designation of person Chief Financial Officer
Place Hyderabad
Date 30-May-2025




Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 SMS Pharmaceuticals Limited VKT Pharma Private Limited Associate Company Sale of goods or services 1700000000 NIL 329256000 132356000 301356000
2 SMS Pharmaceuticals Limited VKT Pharma Private Limited Associate Company Purchase of goods or services 40000000 NIL 0 0 0
3 SMS Pharmaceuticals Limited VKT Pharma Private Limited Associate Company Any other transaction Rent Received 10000000 NIL 1491000 278000 499000
4 SMS Pharmaceuticals Limited SMS Lifesciences India Limited Promoters holding more than 10 % of total equity Purchase of goods or services 200000000 NIL 58236000 -118825000 -62291000
5 SMS Pharmaceuticals Limited SMS Lifesciences India Limited Promoters holding more than 10 % of total equity Sale of goods or services 50000000 NIL 76000 110000 0
6 SMS Pharmaceuticals Limited Raghavendra Engineering Industries Private Limited Relative of Promoter Purchase of goods or services 150000000 NIL 81410000 -19962000 -20261000
7 SMS Pharmaceuticals Limited Raghavendra Engineering Industries Private Limited Relative of Promoter Sale of goods or services 15000000 NIL 0 0 0
8 SMS Pharmaceuticals Limited Eshwar Coal Movers Relative of Promoter Purchase of goods or services 50000000 NIL 3052000 -11794000 -1829000
9 SMS Pharmaceuticals Limited Ramesh Babu Potluri Key Managerial Personnel Remuneration 36523000 NIL 36523000 -4795000 -13863000
10 SMS Pharmaceuticals Limited Vamsi Krishna potluri Key Managerial Personnel Remuneration 48491000 NIL 48491000 -18454000 -27593000
11 SMS Pharmaceuticals Limited Lakshmi Narayana Tammineedi Key Managerial Personnel Remuneration 2086000 NIL 2086000 -270000 -142000
12 SMS Pharmaceuticals Limited Thirumalesh Tumma Key Managerial Personnel Remuneration 897000 NIL 897000 -118000 -111000
13 SMS Pharmaceuticals Limited Shravan Kudaravalli Director Any other transaction Sitting Fees 280000 NIL 280000 0 0
14 SMS Pharmaceuticals Limited Sarvepalli Srinivas Director Any other transaction Sitting Fees 130000 NIL 130000 0 0
15 SMS Pharmaceuticals Limited Suresh Kumar Gangavarapu Director Any other transaction Sitting Fees 250000 NIL 250000 0 0
16 SMS Pharmaceuticals Limited Shanti Sree Bolleni Director Any other transaction Sitting Fees 115000 NIL 115000 0 0
17 SMS Pharmaceuticals Limited Trilok Potluri Director Any other transaction Sitting Fees 115000 NIL 115000 0 0
18 SMS Pharmaceuticals Limited Sunkara Venkata Satya Shiva Prasad Director Any other transaction Sitting Fees 115000 NIL 115000 0 0
19 SMS Pharmaceuticals Limited SMS Peptides Private Limited Subsidiary Company Purchase of goods or services 5000000 NIL 0 0 0
20 SMS Pharmaceuticals Limited SMS Peptides Private Limited Subsidiary Company Sale of goods or services 5000000 NIL 0 0 0
21 SMS Pharmaceuticals Limited SMS Peptides Private Limited Subsidiary Company Any other transaction Rent Received 200000 NIL 0 0 0
22 SMS Pharmaceuticals Limited SMS Peptides Private Limited Subsidiary Company Investment 10000000 NIL 0 0 0
23 SMS Pharmaceuticals Limited Sarath Kumar Pakalapati Director Any other transaction Sitting Fees 0 NIL 0 0 0
24 SMS Pharmaceuticals Limited Neelaveni Thummala Director Any other transaction Sitting Fees 0 NIL 0 0 0
Total value of transaction during the reporting period 562523000